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Abstract 
α1-microglobulin (A1M) is a ubiquitous plasma and tissue protein which has 
reductase and radical- and heme-binding properties. A1M is encoded by the α1-
microglobulin-bikunin precursor (AMBP) gene together with the proteinase 
inhibitor bikunin and the primary site of synthesis is in the liver. Several molecular 
mechanisms have been shown for A1M, and it has been found to be protective in 
vivo in animal models of oxidative stress-related diseases, but its biological role is 
not fully understood. The aim of this thesis was to deepen the knowledge about the 
different biological functions. These studies suggest several possible biological 
functions not previously described. Firstly, A1M was found to be necessary for the 
correct synthesis of bikunin, since the lack of A1M lead to misfolding and/or 
aggregation of bikunin. Secondly, A1M was found to provide red blood cell (RBC) 
stability and could to protect RBCs from hemolysis induced spontaneously or by 
osmosis, heme or radicals. Thirdly, A1M was found to bind to heparin both in vitro 
and in vivo, which may represent both a biological function of A1M as well as a 
biotechnological tool for purifying A1M from plasma. Lastly, a possible biological 
role of A1M as a protector against radicals formed during the illumination of 
riboflavin was shown where the A1M protein is cleaved upon reaction and parts of 
the riboflavin molecule are covalently attached to A1M. The results from these 
studies provide a deeper understanding of how A1M operates in the body and 
elucidates the biological mechanisms of A1M.  
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Populärvetenskaplig sammanfattning 
Bakgrund 
Fria radikaler är atomer eller molekyler som är reaktiva och därmed skadliga för 
kroppen. Oxidativ stress är ett tillstånd som uppstår när mängden fria radikaler i 
kroppen ökar och balansen mellan de fria radikalerna och kroppens egna anti-
oxidanter rubbas. I kroppens normaltillstånd ser antioxidationsförsvaret till att de 
skadliga fria radikalerna motarbetas. På så sätt skyddas våra vävnader. Oxidativ 
stress kan uppstå i kroppen av flera olika anledningar. Det bildas exempelvis fria 
radikaler vid cigarrettrökning och även strålning från solen kan skapa fria radikaler 
i huden när den utsätts för sol. Denna avhandling fokuserar på den kroppsegna anti-
oxidanten α1-mikroglobulin (A1M), ett litet plasma- och vävnadsprotein som finns 
i däggdjur, fiskar, fåglar och reptiler. A1M bildas primärt i levern, varifrån det 
transporteras till kroppens alla vävnader via blodet. Ett flertal olika funktioner har 
påvisats hos A1M. Det kan bland annat oskadliggöra fria radikaler genom reduktion 
(motsatsen till oxidation) samt genom att binda radikalerna till sig och därmed 
neutralisera dem.  
Syfte 
Trots många års studier av A1M, i vilka flera olika molekylära funktioner har 
bevisats, har dess primära funktion i kroppen inte fastställts. Avhandlingens syfte är 
att fördjupa kunskapen om den biologiska funktionen hos A1M. Detta har åstad-
kommits med fyra olika studier. 
Resultat och diskussion 
Studie I 
Genom att klippa bort den bit av arvsmassan som existerar för att tillverka A1M i 
möss, skapades en mus som saknar A1M. Detta gav oss möjligheten att studera vad 
som sker med mössen vid avsaknad av A1M. En intressant företeelse med A1M är 
att det bildas tillsammans med ett annat protein, nämligen bikunin. Denna gemen-
samma produktion av de två proteinerna har bevarats i samtliga djurarter genom 
evolutionen, men någon gemensam funktion efter att de lämnat levern har inte på-
visats. Resultaten från studien visar att A1M är viktigt för att bikunin ska produceras 
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på ett korrekt sätt. Hypotesen är att A1M agerar som ett hjälpprotein. Studien visade 
även, något oväntat, att mössen som saknade A1M blev signifikant tyngre än de bur-
kamrater som hade A1M i sina kroppar. Någon slutgiltig förklaring till viktökningen 
kunde dock inte fastställas men i studien påvisades att en viss ökning av fettinlagring 
i levern sker, vilket kan vara en bidragande faktor.  
Studie II 
De röda blodkropparnas huvudsakliga funktion är att transportera syre från våra 
lungor och ut till kroppens alla delar. Vid olika sjukdomstillstånd, till exempel vid 
malaria, går de röda blodkropparna sönder. Detta kallas för hemolys. Hemolys leder 
till att de röda blodkropparnas innehåll läcker ut, vilket gör att kroppen dels har 
svårare att transportera syre, dels till lokala skador vid området där hemolysen sker. 
De lokala skadorna sker till viss del på grund av bildandet av fria radikaler. De fria 
radikalerna som bildas vid hemolys kan även i sin tur skapa ytterligare hemolys 
genom att skada cellmembranet. I studie II konstaterades att A1M kan stabilisera de 
röda blodkropparna samt skydda dem från hemolys orsakad av radikaler, genom att 
reducera och/eller binda radikalerna till sig. Förmågan att skydda de röda blod-
kropparna är en biologisk funktion hos A1M som inte påvisats tidigare.  
Studie III 
I en studie publicerad av en annan forskargrupp år 2016 påvisades det att A1M är 
ett så kallat heparin-bindande protein. Heparin, och det snarlika heparansulfat (HS), 
är sockermolekyler som finns på de flesta cellytor i vår kropp. Flera olika proteiner 
har utvecklat en förmåga att binda till heparin och HS som en del av sin biologiska 
funktion. I studie III användes flera olika metoder för att studera den heparin-
bindande förmågan hos A1M. Bindningen visades vara av elektrostatisk karaktär 
som därför kan brytas genom att salt adderas. Därutöver påvisades att A1M finns på 
samma platser som HS i flera olika organ i möss samt på ytan av mänskliga celler 
från blodkärl. Resultaten tyder även på att de molekylära funktionerna hos A1M är 
delvis nedsatta när A1M är bundet till heparin eller HS. Förmågan att binda till HS 
på cellytor, vilket möjliggör en ansamling av A1M vid cellytan, utgör troligtvis en 
viktig biologisk funktion hos A1M. Den heparin-bindande förmågan kan även 
utnyttjas för att rena A1M från blod.  
Studie IV 
Vitamin B2, även kallat riboflavin, är ett essentiellt vitamin som fyller flera viktiga 
funktioner i kroppen vid bland annat metabolismen. När riboflavin utsätts för ljus, i 
till exempel huden eller ögonen, bildas fria radikaler som i sin tur kan skada 
kroppens vävnader. I studie IV studerades interaktionen mellan A1M och riboflavin 
under belysning. Resultaten visade att A1M binder riboflavinet till sig, samtidigt 
som ena änden av A1M klyvs bort. Att en bit av A1M klyvs bort när det binder 
radikaler har påvisats tidigare och kan vara en generell mekanism för A1M vid 
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radikalbindning. Studien visade även att A1M kunde skydda mänskliga näthinne-
celler från riboflavinradikalerna. I huden och ögonen är både riboflavin och A1M 
närvarande, vilket gör att bindandet och oskadliggörandet av radikaler från belyst 
riboflavin är en trolig biologisk funktion hos A1M.  
Slutsats 
I den här avhandlingen har de olika molekylära funktionerna hos A1M satts i ett 
mer biologiskt perspektiv än i tidigare forskning. Framtida forskning kommer 
förhoppningsvis leda till ett mer slutgiltigt svar angående den sanna biologiska 
funktionen hos A1M och även till utvecklingen av A1M som ett läkemedel mot 
sjukdomar med oxidativ stress som en drivande faktor.  
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Abbreviations 
A1M  α1-microglobulin 
ROS  Reactive oxygen species 
ETC  Electron transport chain 
O2•-  Superoxide anion 
H2O2  Hydrogen peroxide 
OH•  Hydroxyl radical 
NO  Nitric oxide 
ONOO-  Peroxynitrite 
ER  Endoplasmic reticulum 
CYP  Cytochrome P450 
HO  Heme oxygenase 
FAD  Flavin adenine dinucleotide 
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1Rib*  Singlet excited state riboflavin 
3Rib*  Triplet excited state riboflavin 
SOD  Superoxide dismutase 
CAT  Catalase 
GPx  Glutathione peroxidase 
GSH  Glutathione 
Trx  Thioredoxin 
Prx  Peroxiredoxin 
GST  Glutathione S-transferase 
NRF2  Nuclear factor 2-related factor 2 
ARE  Antioxidant response element 
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KEAP1 Kelch-like ECH-associated protein 1 
PTM Posttranslational modification 
UPR Unfolded protein response 
ERAD ER associated protein degradation 
BiP Binding immunoglobulin protein 
XBP1 X-box binding protein 1
CHOP C/EBP homologous protein
RBC Red blood cell
Hb Hemoglobin
metHb Methemoglobin
HbF Fetal hemoglobin
GAG Glycosaminoglycan
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CS Chondroitin sulfate
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AMBP Alpha-1-microglobulin-bikunin precursor
t-A1M Truncated A1M
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IVH Intraventricular hemorrhage
PE Preeclampsia
PRRT Peptide receptor radionuclide therapy
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Introduction 
Oxidative stress 
Background 
The human body is constantly exposed to external and internal stressors in the form 
of oxidizing and/or reducing substances and this represents a threat against the 
integrity, structure and functioning of our tissues and cells. The damaging nature of 
such agents results in a biological condition referred to as oxidative stress. This has 
been defined as a disturbance in the balance between the occurrence of reactive 
oxygen species/nitrogen species (ROS/RNS) and the inherent ability to counteract 
the oxidation through an antioxidative protective system. 
Endogenous ROS 
The main endogenous source of ROS is the electron transport chain (ETC) where, 
at the inner mitochondrial membrane, energy is generated as ATP. During this 
process, electron carriers NADH and FADH2 transfer electrons via complexes I-IV 
to oxygen to generate ATP and H2O. However, some electrons leak from the inner 
membrane and react with oxygen forming superoxide anions (O2•-) [1]. The O2•- can 
further react with other molecules to form hydrogen peroxide (H2O2) and hydroxyl 
radicals (OH•). RNS can also be produced by O2•- through reaction with nitric oxide 
(NO) forming peroxynitrite (ONOO-). Consecutive reactions can generate other 
RNS such as nitrogen dioxide (•NO2) and nitrosoperoxycarbonate (ONOOCO2-).  
Another significant source of ROS is the endoplasmic reticulum (ER). During 
protein folding, disulfide bonds are formed in an oxidative process which requires 
O2•- and approximately 25% of intracellular O2•- is produced within the ER [2]. This 
can be increased in cells which secrete large amounts of proteins and during ER-
stress where the ER attempts to refold misfolded proteins.  
Xenobiotics, which are chemical substances that are not normally present or 
produced in the body, can cause oxidative stress when they are broken down by 
enzymes. One of the most studied group of enzymes involved in the metabolism of 
xenobiotics is the cytochrome P450 (CYP) family. CYP enzymes are very versatile 
and are involved in a wide range of biochemical reactions often involving substrate 
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oxidation [3]. When CYP reacts with its substrate, ROS are produced in the form of 
H2O2 and O2•. 
Exogenous ROS 
Ultraviolet light (UV) is divided into UV-A (long waves), UV-B (medium waves), 
and UV-C (short waves). UV makes up a portion of the sunlight, where UV-A and 
a small portion of UV-B reaches the surface of the earth. UV-C and most of UV-B 
are blocked by the ozone layer. The UV-B light reaching the skin can penetrate the 
epidermis to reach the dermis, where it can induce OH• formation from H2O2. 
Additionally, absorption of UV-B by thymine or cytosine can cause direct damage 
to DNA. UV-A is less effective in causing DNA-damage since it has less photon 
energy. However, UV-A can penetrate the epidermis to a higher extent than UV-B, 
where it can induce formation of H2O2 and singlet oxygen (1O2). 
If the energy of a photon is sufficiently high, it can displace an electron from a non-
radical, leaving a radical cation (X•+) behind. UV-A and UV-B do not have enough 
energy to ionize, but γ-rays, X-rays, α-particles and β-particles can, and their 
radiation is therefore referred to as ionizing [4].  
ROS-induced damage 
Uncontrolled levels of ROS can lead to oxidation of various biological molecules 
including lipids, proteins and DNA. Hydroxyl radicals can cause lipid peroxidation 
of the plasma membrane in any cell or organelle with polyunsaturated fatty acid side 
chains. A carbon-centered radical (C•) is formed by abstraction of a hydrogen from 
the hydrocarbon sidechain. With oxygen present, a peroxyl radical (-C-O-O•) is 
formed, which is capable of abstracting a hydrogen atom from an adjacent fatty acid, 
propagating the reaction. High levels of lipid peroxidation lead to loss of membrane 
function and fluidity, and potentially activation of the apoptotic cascade [4]. 
Proteins are common targets for ROS due to their abundance in most systems within 
the human body. ROS-induced damage to proteins can result in backbone 
fragmentation, alterations in side-chain hydrophobicity, protein unfolding, 
conformational changes and aggregation via covalent cross-linking. These changes 
can alter the interaction between the protein and its biological partner or ligand, 
potentially obstructing the functionality of the protein [5]. Similar to the lipid 
peroxidation, with oxygen being present, peroxyl radicals and peroxides are formed, 
which can in turn oxidize nearby biomolecules and thereby propagate the reaction. 
DNA modified through oxidation is abundant in several human tissues, especially 
in tumors [6]. To avoid accumulation of oxidatively modified DNA, many defense 
and repair mechanisms have evolved [7]. Despite these mechanisms, DNA 
mutations are unavoidable which results in cancer, inheritable diseases and ageing.  
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Excessive levels of ROS cause damage to all cellular constituents unless controlled. 
Conversely, at low to moderate concentrations, ROS act as important mediators in 
different signaling processes. Humans have evolved enzymes such as nitric oxide 
synthase (NOS), which generates NO, and NADPH oxidase producing O2•-, to use 
as signaling molecules for several different biological functions [8]. 
Heme 
The heme molecule and its toxicity play a central role in this work due to both its 
role in oxidative stress and the heme binding function of α1-microglobulin (A1M). 
Its toxicity towards red blood cells and the protective effect of A1M are the main 
foci of paper II.  
The heme molecule is a porphyrin complex with an 
iron atom chelated in its core (Figure 1). Heme is 
fundamental for aerobic organisms, due to is role in 
numerous different biological functions [9]. It is 
involved in oxygen transport, as part of hemoglobin 
and myoglobin and it functions as the active part of 
various heme-proteins [10]. Cytochrome c contains 
a heme group in its active site [11], where it is used 
for electron transport and energy generation. 
Cytochrome c has also been shown to play a role in 
the apoptosis cascade [12]. Another important heme 
protein is catalase which contains four heme 
groups, allowing it to react with H2O2 forming H2O 
and O2 [13]. The NO producing enzyme NOS, 
mentioned above, contains a heme molecule as a functional group [14]. The most 
abundant heme-protein is hemoglobin, which contains four subunits each carrying 
one heme group [15].  
The catabolism of heme in mammals results in biliverdin, CO and iron. Firstly, heme 
oxygenase (HO) converts heme, with the help of cytochrome P450 reductase, to 
biliverdin [16]. Biliverdin is further converted to bilirubin by biliverdin reductase, 
which requires NADPH as an electron donor [17]. Bilirubin, when bound to 
albumin, acts as an antioxidant [18]. When bound to albumin, bilirubin is excreted 
from the liver through the bile. Through bacterial decomposition, bilirubin is finally 
converted to stercobilin and excreted in the feces.  
When bound to its protein, heme acts as a functional group. However, when heme 
is released from its protein, or if the heme containing protein is moved from its 
protected environment, e.g. extracellular hemoglobin, it can oxidize nearby bio-
molecules causing damage to cells and tissues [9]. Accumulation of free labile heme 
and hemoglobin in large quantities occurs during pathological states with hemolysis 
Figure 1. Molecular structure of heme 
with the iron atom in its ferric state 
(Fe2+) 
26 
such as sickle cell disease, malaria, intraventricular hemorrhage [19] and pre-
eclampsia [20]. Newly synthesized heme groups not yet incorporated into 
hemeproteins also adds to the labile heme pool. The redox active iron in the free 
heme group allows it to participate in the Fenton reaction, producing OH•, which 
leads to oxidative damage of lipid membranes, nucleic acids, and proteins. The 
release of free heme groups can also cause inflammation through activation of 
proinflammatory transcription factors [21]. The toxicity of free heme is further 
exacerbated by the hydrophobicity of heme, which enables it to intercalate into cell 
membranes, increasing the susceptibility of cells to oxidation mediated damage 
through the formation of lipid peroxides [22]. Heme has also been shown to act as a 
catalyst during the oxidation of low-density lipoprotein (LDL), which causes 
toxicity to the endothelium [23,24]. Finally, the free heme released from hemoglobin 
during hemolysis can damage the membranes on nearby RBCs, causing a feed-
forward loop resulting in more hemolysis [25].  
To defend the tissues against heme toxicity, the human body has developed several 
different systems (Figure 2). Cells exposed to heme, up-regulate the heme degrading 
protein HO and the iron storing protein ferritin. Studies on HO-1 deficient knockout 
mice showed very high concentrations of circulating heme [26]. The primary 
defense against circulating heme is hemopexin (Hpx) which is a plasma protein with 
high binding affinity for free heme [27]. When the free heme group is bound to Hpx 
it is transported to the liver where it is taken up by parenchymal cells and degraded 
by HO [28]. Another heme binding protein found in plasma is α1-microglobulin, 
which can also bind heme intracellularly [29]. The primary source of circulating 
heme is from hemoglobin, which if not contained within the RBC can cause 
oxidative damage. To protect against hemoglobin induced damage, during for 
example hemolysis, the plasma protein haptoglobin (Hp) can bind Hb. The resulting 
Hb-Hp complex is then removed by macrophages through binding to CD163 [30].  
Figure 2. Overview of protective mechanisms against extracellular Hb, free heme and iron. In circulation, 
haptoglobin binds extracellular Hb. When the extracellular Hb is broken down into free heme this is bound by 
hemopexin and A1M. Intracellularly, free heme, released from heme proteins or newly synthesized, is bound by 
A1M or broken down by HO-1. The breakdown of the heme group by HO-1 results in free iron which is neutralized 
by ferritin. 
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Riboflavin  
Another important molecule that plays a central role in this work is riboflavin. Its 
toxicity during illumination and its interaction with A1M are studied in paper IV. 
Riboflavin (7,8-dimethyl-10-ribityl-isoalloxazine), more commonly known as 
vitamin B2, is a water-soluble essential vitamin found in milk, meat and leafy 
vegetables. Riboflavin is mostly found as a component of the prosthetic group flavin 
adenine dinucleotide (FAD) and flavin mononucleotide FMN, but can also be found 
in its free form [31]. Riboflavin, FAD and FMN can exist in different redox states; 
oxidized (quinone), one-electron reduced (semiquinone) and two-electron reduced 
(hydroquinone), enabling transportation of single electrons, hydrogen atoms and 
hydride ions. Both FAD and FMN are involved in several enzymatic reactions 
throughout metabolism.  
When illuminated, riboflavin rapidly undergoes photo-degradation, generating ROS 
and thereby classifying it as a photosensitizer. During the photo-degradation, 
riboflavin is broken down into different molecules, where lumiflavin, lumichrome 
and formylmethylflavin represent the majority of products formed at physiological 
pH [31]. Photo-degradation generates a very fluorescent short-lived singlet excited 
state riboflavin (1Rib*). Subsequently, 1Rib*, through an intersystem crossing, is 
converted into the triplet excited state riboflavin 3Rib*, which is more long-lived. 
3Rib* is a bi-radical and powerful oxidant, which can oxidize proteins, lipids and 
DNA [32]. The direct reaction between 3Rib* and different biomolecules is termed 
the type I reaction [33]. The type I reaction generates O2•- which can further react 
with other molecules forming H2O2 and OH• [34]. 3Rib* can also transfer its 
excitation energy to O2 forming the more unstable and reactive singlet oxygen (1O2). 
The latter reaction is termed the type II reaction [33]. The type I and II reactions are 
summarized in Figure 3. 
 
 
 
Figure 3. Photosensitization of riboflavin by the type I or type II mechanism. 
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Riboflavin (free form), FAD and FMN are all involved in metabolism and are 
therefore mostly found in organs with a high metabolic activity. However, they are 
also present in tissues that are exposed to light, such as skin and eyes [34]. This 
makes the light-exposed organs vulnerable to radicals formed from the photo-
degradation of riboflavin. The riboflavin-generated radicals can react with proteins, 
DNA and lipids, which can cause cell death, mutations and potentially 
carcinogenesis [35]. Previous studies have shown that DNA mutations induced by 
UVA-light in fibroblasts are increased severalfold with riboflavin present as a 
photosensitizer [36]. Additionally, oxidative stress is involved in causing a wide 
range of eye diseases such as rhegmatogenous retinal detachment (RDD), age-
related macular degeneration (AMD), glaucoma and cataracts [37-40].  
Endogenous antioxidation defense 
To protect cells and tissues against damage from oxidative stress, several different 
proteins and molecules with antioxidative properties have evolved. The anti-
oxidation system can be divided into two different categories: enzymatic and non-
enzymatic. 
Enzymatic antioxidants 
The antioxidant superoxide dismutase (SOD) catalyzes the dismutation of O2•- 
forming O2 and H2O2 [41]. Three different SOD variants have been reported: soluble 
(SOD1), mitochondrial (SOD2) and extracellular (SOD3). SOD has been shown to 
be of primary importance for the prolongation of lifespan. Studies have revealed 
that mice lacking SOD1 [42] or SOD2 [43] suffer from immense oxidative stress, 
which leads to a severely reduced lifespan and a wide range of pathologies. H2O2 
produced from the dismutation of O2•- is a reactive molecule that needs to be further 
processed. This is achieved by the enzymatic antioxidant catalase (CAT), which 
catalyzes the breakdown of H2O2 into H2O and O2 [13]. The breakdown of H2O2 can 
also be executed by another enzymatic antioxidant, glutathione peroxidase (GPx). 
GPx, together with glutathione (GSH) converts H2O2 into H2O and glutathione 
disulfide (GSSG) [44]. The GSSG is reduced back to GSH by glutathione reductase 
(GR) with NADPH as an electron donor.  
Thioredoxin (Trx) is an important enzymatic antioxidant which plays a role in 
several biological processes. Trx contains a CGPC motif, where the cysteine 
residues play a central role in breaking disulfide bonds in oxidized proteins [45]. In 
the process, a disulfide is formed between the cysteine residues in the CGPC motif, 
which is broken by thioredoxin reductase (TrxR) using NADPH.  
Peroxiredoxin (Prx) is one of the most abundant proteins in RBCs apart from 
hemoglobin. Its primary targets are H2O2 and ONOO-. Prx has a redox-active 
cysteine residue in its active site, which is oxidized to a sulfenic acid by the substrate 
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[46]. The sulfenic acid is reduced back to a free thiol by Trx, GSH or glutathione S-
transferase (GST). GST is a detoxification enzyme with a wide range of functions. 
However, the main function of GST is to detoxify xenobiotics by catalyzing the 
conjugation of GSH to the xenobiotic, to prevent it from interacting with bio-
molecules [47].  
The expression of the above described enzymatic antioxidants, including A1M, is 
regulated by nuclear factor 2-related factor 2 (NRF2). Under non-stressed 
conditions, NRF2 is bound to Kelch-like ECH-associated protein 1 (KEAP1), which 
is ubiquitinated and degraded in the proteasome. During oxidative stress, NRF2 is 
released from KEAP1 and translocated to the nucleus. NRF2 induces the expression 
of antioxidants through binding to the antioxidant response element (ARE) present 
in the promotor region of the genes [48]. 
Non-enzymatic antioxidants 
Non-enzymatic antioxidants are low molecular weight compounds, such as vitamin 
C and E, carotenoids, uric acid and GSH. Vitamin C, also known as ascorbic acid, 
is a water-soluble vitamin found in high doses in fruit and vegetables. Vitamin C 
can scavenge both OH• and O2•- and it is one of the key antioxidants in the blood 
[49,50]. Vitamin E is a group of tocopherols and tocotrienols, which are fat-soluble 
antioxidants able to protect cell membranes against ROS. Vitamin E can donate a 
hydrogen atom to the radical to minimize the damaging effects [51]. The oxidized 
vitamin E can be recycled through reacting with a hydrogen donor, for example 
vitamin C [52].  
Carotenoids are brightly colored fat-soluble pigments present in fruits and 
vegetables. The most studied of the carotenoids, which are also present in human 
tissues, are β-carotene and lycopene [53]. Carotenoids have radical scavenging 
abilities and can for example quench peroxyl radicals and thereby prevent 
propagation of the reaction.  
Uric acid is a strong reducing agent that is found in the blood, where it together with 
vitamin C makes up most of the antioxidant capacity [54]. Uric acid has been shown 
to selectively bind ONOO- and inactivate it [55].  
Finally, glutathione (GSH) is a tripeptide comprised of cysteine, glutamic acid and 
glycine. It is highly abundant in all cell compartments and it is one of the major 
soluble antioxidants. GSH can exist in its reduced (GSH) or oxidized form (GSSG) 
and the ratio between these two states is a common determinant of oxidative stress. 
GSH has several different antioxidant functions [56]. As described above, it can 
detoxify H2O2 together with GPx, followed by recycling to GSH through reduction 
by GR. It can also reduce vitamin C and E back to their active forms.  
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ER-stress 
Protein folding and posttranslational modification 
The biological function of a protein is dependent on its three dimensional (3D) 
native structure, which is encoded in the protein’s amino acid sequence. Several 
different factors determine how a protein is folded [57], such as hydrogen bonds 
[58], van der Waals interactions, backbone angle preferences, electrostatic inter-
actions, hydrophobic and hydrophilic interactions [59] and chain entropy. Another 
important part of the protein folding machinery are the molecular chaperones, which 
aid in the folding process [60]. Molecular chaperones bind to the folding protein and 
stabilize the otherwise unstable protein structures. The chaperones do not know how 
the protein is supposed to be folded, but operate to prevent improper folding 
conformations [61].  
Oxidative protein folding 
Several proteins depend on disulfide bonds for their folding and function and they 
are crucial to the structure and stability of the protein. Mispairing of cysteine 
residues is a common cause of misfolding. The formation of disulfides is a 
spontaneous process, but it is dependent on a redox reaction, making it very slow 
[62]. Protein disulfide isomerase (PDI) is a protein that can rearrange incorrect 
sulfides. In addition, PDI can catalyze disulfide formation and reduction [63]. For 
PDI to be able to catalyze the formation and rearrangement of disulfides it needs to 
be re-oxidized, which is carried out by ER oxidoreductin 1 (Ero1p) [64]. For the 
Ero1p to become oxidized again, it uses a flavin dependent reaction to transfer 
electrons to molecular oxygen [65]. This results in the generation of ROS, making 
it a source of oxidative stress in the cell.  
Posttranslational modifications 
After being translated, most proteins undergo a process called posttranslational 
modification (PTM), where the proteins are covalently modified. PTMs can be 
divided into two different categories, where the first category includes hydrolytic 
cleavage of one or more peptide bonds within the protein by proteases. The hormone 
insulin, for example, is translated as a single chain inactive prohormone which is 
then cleaved by a protease to generate the active two-chain form of insulin [66]. The 
second category is the covalent addition of one or more groups to the amino acids 
of the protein, such as glycosylation, acetylation or phosphorylation. This extends 
the chemical repertoire of the 20 amino acids by introducing new functional groups 
or by modifying existing ones [67].  
Glycosylation, which is relevant to this work, is the enzymatic process where a 
glycan is attached to an amino acid sidechain. The list of biological effects due to 
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glycosylation of proteins is almost endless and more effects are added frequently 
[68]. For example, some proteins do not fold properly unless they are correctly 
glycosylated [69], and glycosylation also affects the solubility of the protein. 
Glycans also function as recognition markers, modulate immune responses and 
mediate interaction with pathogens. The process of glycosylation involves 13 types 
of monosaccharides which are attached to 8 types of amino acids and is performed 
by several different enzymes. This results in 5 classes of glycans being produced: 
N-linked (attached to a nitrogen of an asparagine or arginine side-chain), O-linked
(attached to the hydroxyl oxygen of a serine, threonine, tyrosine, hydroxylysine or
hydroxyproline side-chain), phosphoglycans (attached to the phosphate of a
phosphoserine side-chain), C-linked glycans (attached to a tryptophan side-chain)
and glypiation (addition of a GPI anchor linking the protein to a lipid through glycan
linkages). Two glycans, that are of importance for this work, are the O-linked
glycosaminoglycans (GAGs) heparan sulfate and chondroitin sulfate, which will be
covered in more detail below.
ER-stress and the unfolded protein response 
Most secreted and transmembrane proteins are folded within the endoplasmic 
reticulum (ER). Malfunctioning protein folding results in the accumulation of 
unfolded and misfolded proteins, leading to an overload state called ER-stress. To 
restore the cellular homeostasis, the unfolded protein response (UPR) is triggered 
[70], which leads to expansion of the ER membrane, where the additional space is 
used for increased protein folding machinery, such as chaperones [71]. 
Simultaneously, the influx of newly translated proteins progressing into the ER is 
decreased to handle the increased unfolded and misfolded protein load. To further 
combat the ER-stress, the ER-associated protein degradation (ERAD), which 
removes unfolded and misfolded proteins, is increased [72]. The ER-stress also leads 
to an up-regulation of antioxidants due to an increased production of ROS [73]. If 
the ER-stress is persistent, the activation of CHOP can lead to apoptosis [74]. 
UPR signaling 
UPR signaling is mediated through three different transmembrane transducers: 
proteinase kinase RNA-like ER-kinase (PERK), activating transcription factor-6 
(ATF6) and inositol-requiring enzyme-1α (IRE1α) [75-77]. Under normal 
unstressed conditions, binding immunoglobulin protein (BiP) forms a stable 
complex with PERK, IRE1α and ATF6. A build-up of unfolded or misfolded 
proteins leads to a reversible dissociation of the BiP-PERK/IRE1α/ATF6 
complexes, initiating downstream signaling of the UPR [78]. The active PERK 
phosphorylates the eukaryotic initiation factor 2α (eIF2α), which leads to a general 
decrease in protein synthesis [77]. However, not all proteins are affected by the 
decrease in synthesis. This is due to certain regulatory sequences in the mRNA, 
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bypassing the translational stop. One of the mRNAs which has an increased 
translation in the presence of eIF2α is the transcription factor ATF4, which is 
involved in increasing the antioxidant response through NRF2 [79]. ATF4 also 
activates the apoptosis signaling protein C/EBP homologous protein (CHOP) [74]. 
After activation of IRE1α, it removes parts of the X-box binding protein 1 (XBP1) 
mRNA, forming the splice product XBP1s, which is a highly active transcription 
factor that increases the production of ER chaperones, enhancing ER biogenesis and 
induces ERAD [80]. Dissociation of BiP from AFT6 results in a translocation of 
ATF6 to the Golgi apparatus, where it is proteolytically cleaved by SP1 and SP2 
into an active transcription factor (ATFNT) [81]. This results in an increased 
expression XBP1 and chaperones. The signaling pathways are illustrated in Figure 
4.  
Figure 4. Signaling pathways during the unfolded protein response (UPR). Dissociation of BiP from PERK, IRE1α 
and ATF6 leads to activation of three downstream signaling pathways. PERK activation leads to an increase in 
expression of antioxidants and apoptosis signaling through CHOP. Activation of IRE1α generates the splicing 
product XBP1s, which activates the transcription of chaperones and induces ERAD. ATF6 activation leads to an 
increased transcription of chaperones and XBP1. 
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Red blood cells 
Structure and function 
The red blood cell (RBC) is the most common cell in the body, making up 
approximately 25% of total cells. Their primary function is to bind oxygen in the 
lungs and transport it to the different tissues of the body. The RBCs are produced in 
the bone marrow in a process called erythropoiesis where a hematopoietic stem cell 
undergoes a series of differentiations. In the first step, the hematopoietic stem cell 
becomes a proerythroblast, which then becomes an erythroblast, and in the final 
step, a reticulocyte is formed and released into the blood (Figure 5). The 
reticulocytes comprise roughly 1-2% of the circulating RBCs and after about 1-2 
days they become mature RBCs. As the cells differentiate, several different 
characteristics change. The size of the cells is reduced, and the nucleus and DNA 
are removed. The cells also become redder in color as they start to produce hemo-
globin (Hb). The mature RBCs have a life span of approximately 115 days [82] and 
are later broken down in the spleen.  
 
The RBCs are shaped like biconcave disks, which provides a larger surface area for 
gas exchange to occur. The space within the capillaries is very narrow, requiring the 
RBCs to fold in on themselves to be able to pass through. The extremely flexible 
nature of the RBCs is due to their cytoskeleton, which contains the flexible protein 
spectrin [83]. The RBCs do not have a nucleus or organelles, and due to the lack of 
mitochondria they have to rely on anaerobic glycolysis for ATP generation.  
Figure 5. Erythropoiesis. A pluripotent hematopoietic stem cell differentiates into a proerythroblast which further 
differentiates into an erythroblast. The erythroblast is transformed into a reticulocyte and released into the blood 
stream. While in the blood stream, the reticulocyte matures into a red blood cell (RBC). 
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Hemoglobin 
The lack of organelles in the RBC allows for additional space for oxygen carrying 
Hb molecules. The Hb molecule is composed of four polypeptide globin chains each 
containing a heme group with a chelated iron atom in the ferrous state (Fe2+). In 
adult Hb (HbA), the Hb molecules are made up of two α-chains and two β-chains, 
whereas in the fetal Hb (HbF), the β-chains are replaced by γ-chains. The γ-chains 
provides the HbF with a higher oxygen affinity than HbA, facilitating the oxygen 
transfer from the maternal circulation to the fetal circulation in the placenta [84].  
Oxidative stress in the RBC 
During the lifetime of an RBC, it is continuously exposed to oxidants, which if not 
removed leads to impaired flexibility of the RBCs, making it more difficult for them 
to move through the narrow capillaries. To avoid oxidative stress, the RBCs contain 
an array of antioxidants and reducing enzymes, including SOD, CAT and Prx [85-
87], as well as the non-enzymatic antioxidants vitamin C and vitamin E. For Hb to 
be functional, the iron has to be kept in its ferrous state (Fe2+), whereas the ferric 
state (Fe3+), called metHb, severely weakens the oxygen binding capacity. Hb is 
continuously being auto-oxidized, which leads to the production of metHb, O2•- and 
H2O2 [88]. To avoid auto-oxidation of Hb, and the accumulation of metHb and ROS, 
the enzyme glucose-6-phosphate dehydrogenase (G6PDH) supplies reducing 
energy to maintain the level of NADPH. NADPH in turn keep the levels of reduced 
GSH and GPx high enough to keep the iron in Hb in its ferrous state. Studies on 
patients with mutations in their G6PDH gene, which impairs the function of the 
G6PDH protein, have shown an increase in the levels of free radicals causing 
membrane disruption [89]. 
In the circulation, ROS are being released from neutrophils and macrophages which 
can cause damage to the RBCs. Studies have shown that RBCs are particularly 
susceptible to peroxides formed in the lipid membrane, which contains high levels 
of unsaturated fatty acids [90]. Some of the ROS are also internalized by the RBCs 
and are neutralized by the intracellular antioxidant defense. Membrane disruption 
in RBCs leads to hemolysis, resulting in extracellular Hb in the blood. The 
extracellular Hb can be further broken-down releasing free heme groups. Both the 
free heme groups and the extracellular Hb causes oxidative stress, creating a feed-
forward loop resulting in more hemolysis [25]. This is covered more in detail above. 
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Heparin and heparan sulfate 
Structure 
Heparin and heparan sulfate (HS) are members of the glycosaminoglycan (GAG) 
family of carbohydrates, together with chondroitin sulfate (CS), dermatan sulfate 
(DS), hyaluronic acid (HA) and keratan sulfate (KS).  
Heparin and HS are both linear disaccharide polymers composed of alternating units 
of α-D-glucosamine (GlcN) and either α-L-iduronic acid (IdoA) or β-D-glucuronic 
acid (GlcA). The disaccharides are linked together by (1→4) glyosidic linkages. 
The GlcN subunits in heparin are almost always sulfated. The GlcN subunits of HS 
can either be N-acetylated (GlcNAc) or N-sulfated (GlcNS6S) and these make up 
regions of GlcNS6S (NS domains), GlcNAc (NA-domains) or both types (NS/NA 
domains) (Figure 6). GlcNS6S disaccharides can be further modified by glucuronyl 
C5-epimerization and O-sulfation at positions 2, 3 or 6, which gives theses domains 
diverse properties [91-93].  
HS is primarily found as part of heparan sulfate proteoglycans (HSPG) and the most 
common HSPG families are the syndecans and glypicans. The syndecans are 
transmembrane proteins that bind components of the extracellular matrix (ECM) to 
endothelial cells [94]. The name syndecans comes from the Greek word “syndein”, 
translated to “bind together”. Glypicans are directly linked to membrane phospho-
lipids and this glycosyl phosphatidyl inositol (GPI) linkage is the reason for their 
name [95]. HSPGs are often found in the ECM or on cell surfaces. Membrane bound 
syndecans can be enzymatically shed by several different proteinases, releasing the 
ectodomain of the syndecans [96]. Shedding of the ectodomain is an important 
mechanism regulating paracrine and autocrine signaling. The shedding process is 
increased during pathophysiological events such as wound healing. 
Heparin can be seen as a more sulfated, tissue specific, HS variant which is only 
found within mast cells. Heparin is primarily known as an anticoagulation pharma-
ceutical and it is one of the most used anticoagulants in the world. Heparin exerts 
its anticoagulant activity through binding of antithrombin III, facilitating the 
subsequent inhibition of thrombin and activated factor X, blocking the coagulation 
cascade [97].  
Physiological role and protein binding 
HS in various forms play an important role in a multitude of biological functions, 
including: inflammation [98], anticoagulation, wound healing, receptor- and co-
receptor functions, binding of proteins including growth factors and cytokines [99], 
as well as axonal development and guidance [100]. HS regulates theses biological 
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processes through interactions with a wide range of proteins, known as heparin-
binding proteins (HBPs) [101]. The protein binding properties is dependent on both 
sequence specificity and/or electrostatic interactions. Arginine and lysine, which are 
both positively charged amino acids, are important contributors during binding to 
the negatively charged HS molecule [102]. The multi-functional nature of HS is due 
to the large variations in sulfation and acetylation of the disaccharides constituting 
the molecule, and this large diversity of HS molecules has been titled the heparan-
ome [103].  
Protein binding sequences and heparin binding domains 
The specificity of the binding is contributed to by both protein binding sequences in 
the HS chain and the presence of heparin-binding domains in the sequences of the 
HBPs. The interaction between HS and proteins is dependent on sulfate groups, 
where the NS or NA/NS function as protein binding motifs on the HS chain. The 
first protein binding site that was characterized was to antithrombin III [97], where 
the binding site was found to be a pentasaccharide with a rare modification of the 
sugar backbone. However, the majority of binding sites are dependent on more 
common modifications, arranged in different patterns. The length of the saccharide 
binding sequence has been shown to vary a lot between different interactions, where 
some proteins require a binding sequence of more than 20 saccharides.  
Characterization of general heparin binding domains on HBPs was first attempted 
in the late 80s, where the heparin binding domains of vitronectin, apoE, apoB-100 
and PF-4 were used to find 21 novel HBPs [104]. Since then, several heparin binding 
domains have been determined and found to be enriched with basic amino acids. 
Recently, Manissorn et al characterized HBPs in urine using applied affinity 
purification-mass spectrometry [105]. This resulted in the discovery of numerous 
new HBPs and amongst these was the primary protein of this work, A1M.  
Figure 6. Structure and physiological functions of heparan sulfate (HS). HS is made up of NA- and NS-
domains, which make up binding sites for heparin binding proteins (HBPs). HS can be attached to 
transmembrane proteins or make up parts of the extracellular matrix.  
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α1-microglobulin 
A1M is a small protein found both intra- and extracellularly in most vertebrate 
tissues. It has been described as a housekeeping protein due to its heme-binding 
capacity, reducing abilities and radical trapping properties.  
Structure 
Human A1M consists of a peptide chain 
with 183 amino acids [106] and it has a 
molecular weight of 26 kDa [107]. A1M is 
glycosylated in three different positions, 
two sialylated complex type, biantennary 
and triantennary carbohydrates attached to 
Asn17 and Asn 96, and one O-linked oligo-
saccharide attached to Thr5 [108]. A1M has 
been well conserved during evolution, with 
homologues found and sequenced from 
other mammals, amphibians, fish and birds 
[109-112]. A1M is a member of the 
lipocalin protein family, which is a group 
consisting of 40-50 proteins present in all 
branches of life, such as bacteria, fungi, 
plants and animals [113], and 12 human lipocalins have been described. All lipo-
calins share a similar tertiary structure with a single polypeptide containing 150-190 
amino acids, which forms a β-barrel consisting of eight antiparallel β-sheets with 
one open end and one closed end. Most lipocalins contain a binding site for small 
hydrophobic compounds within the β-barrel [114]. The crystal structure of A1M 
(Figure 7) shows the typical lipocalin fold with a β-barrel with four loops at the 
open end [115]. A1M has an important side chain, Cys34, which is located on loop 
1 at the proximity of the open end of the β-barrel. Cys34 is conserved in all species, 
can participate in one-electron oxidation and reduction reactions, and is involved in 
reductase activities and the binding and neutralization of target compounds [116]. 
When isolating A1M from urine, A1M carries covalent modifications on Lys69, 
Lys92, Lys118, Lys130 and Cys34, and these chromophores have been suggested 
to contribute to the charge heterogeneity and yellow-brown color of the protein 
[117,118].  
 
Figure 7. 3D-strucutre of A1M. Amino acids 
important for molecular mechanisms are shown in 
blue (Lysine), yellow (Tyrosine), green (Histidine) 
and red (Cysteine) with their side chains visible.  
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The AMBP gene 
A1M is encoded by the alpha-1-microglobulin-bikunin precursor gene (AMBP) 
which also encodes bikunin [119,120]. Bikunin is a Kunitz-type plasma proteinase 
inhibitor and a structural component of the extracellular matrix [121,122]. The 
AMBP gene has 10 exons where exons 1-6 encode A1M and exons 7-10 encode 
bikunin (see Figure 8). After transcription of the AMBP gene and translation of the 
resulting mRNA, the AMBP precursor protein is formed with A1M and bikunin 
linked together by a tripeptide [123]. The AMBP precursor is then folded in the ER, 
followed by transportation to the Golgi, where a chondroitin sulfate chain is attached 
to the N-terminal of the bikunin. After leaving the Golgi, heavy chains (HC) HC1, 
HC2 and HC3 are covalently bound to the chondroitin sulfate chain [124]. The 
attachment of the HC later results in the formation of inter-α-trypsin inhibitor (IαI), 
which consists of bikunin, HC1 and HC2, or pre-α-inhibitor (PαI), which consists 
of bikunin and HC3 [125]. Finally, the AMBP precursor is proteolytically cleaved 
between A1M and bikunin, and the IαI, PαI and A1M are secreted separately from 
the cell [126]. No functional or physical connection between A1M and bikunin or 
its complexes has been found and the reason for co-synthesis is unknown. However, 
A1M has recently been shown to be important during synthesis and posttranslational 
modification of bikunin [127]. Similar to other enzymatic antioxidants, the 
expression of A1M has been shown to be regulated through the KEAP1/NRF2 
signaling system [128,129].  
Figure 8. Structure of the AMBP gene and posttranslational modifications of A1M and bikunin. The AMBP gene 
contains 10 exons, where exon 1-6 encode A1M and exon 7-10 encode bikunin. After translation, A1M is O- and 
N-linked glycosylated and a chondroitin sulfate chain is attached to bikunin. Heavy chains (HC) are attached to the 
chondroitin sulfate chain, forming inter-α-inhibitor and pre-α-inhibitor. The two proteins are then cleaved and 
secreted separately. Figure from [127]. 
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Cloning of the AMBP gene in humans [130] and mice [131] mapped the gene to the 
lipocalin gene cluster at the 9q32-33 region in man [130] and to chromosome 4 in 
mice [132]. Between exon 6 and 7, there is a large intron containing retroposons and 
other repeated sequences, which suggests that this a recombinatorial hot spot [131]. 
This might have provided a foundation for the fusion between an ancestral bikunin 
gene and an ancestral A1M gene. The genetic construction of the AMBP gene has 
been shown to be conserved in all species where A1M has been studied.  
Synthesis, distribution and catabolism 
The primary site for A1M synthesis is the liver [133], but it is also expressed at a 
lower rate in peripheral organs. From the liver, it is secreted to the blood where it is 
found in either its free form, which has the Cys34 in a free functional state, or bound 
to IgA with a reduction resistant disulfide bond including Cys34 [134]. Minor 
complexes have also been found with albumin and prothrombin [135]. Complexed 
forms of A1M are present in all studied species, but with different complex-partners, 
indicating evolutionary conservation of complex formation ability. The plasma 
concentration of A1M is approximately 20-50 mg/ml [136], with men having 
marginally higher levels than women [137]. The main sites of A1M localization are 
in the liver, blood plasma and kidneys [138]. A1M and its complex forms are quickly 
equilibrated between the intra- and extravascular compartments with a half-life in 
blood of approximately 2-3 min [139].  
The presence of A1M mRNA, other than in the liver, has been identified in most 
other cell types and the A1M protein has been detected in the perivascular 
connective tissue of most organs [140-142], where it is often colocalized with elastin 
and collagen. In vitro studies have shown that A1M can bind directly to collagen 
[142]. During pregnancy, A1M is located at the interface between the maternal blood 
and the fetal tissue in the placenta [143].  
A1M has also been shown to bind to the surface of a wide variety of cells, including 
keratinocytes, blood cell lines, lymphocytes and neutrophils [142,144,145]. The 
binding of A1M to the cell surface is specific for A1M, saturable and sensitive to 
trypsin, indicating the presence of an A1M receptor. However, no specific receptor 
has been identified yet.  
A1M is found intracellularly, where it partly is located to the mitochondrial 
respiratory chain bound to Complex I [146]. Uptake and mitochondrial localization 
of exogenously added A1M in vitro has been shown in keratinocytes, blood cells 
and liver cells, and RBCs have also been shown to contain cellular A1M [25]. 
Mutated A1M, which lacks Cys34, showed a lower cellular uptake indicating an 
important role of Cys34 in the uptake mechanism [147]. The functional role of A1M 
intracellularly has not been established, but it has been shown that its presence 
lowers the redox charge and increases the levels of free protein thiol groups in the 
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cytosol [144]. It was also speculated that mitochondrial A1M is involved in 
maintaining mitochondrial energy delivery during apoptosis [146]. During normal 
mitochondrial respiration, O2•- is leaking from Complex I and III. A1M has therefore 
been hypothesized to act as a radical scavenger, counteracting and eliminating the 
leaking O2•-, and thereby preventing oxidative damage to nearby molecules. The 
uptake of A1M in RBCs was shown to play a minor role in protection against 
hemolysis, suggesting a non-hemolysis related function in the cytosol of RBCs [25]. 
The final destination for A1M is the kidneys, passing through the glomerular 
membranes to the primary urine, where the large majority is reabsorbed by the 
proximal tubular cells and catabolized [148]. Notable levels of A1M are secreted in 
the urine, making it a sensitive and clinically used indicator of tubular renal damage 
[107]. The life cycle of A1M is illustrated in Figure 9. 
Figure 9. The life cycle of A1M. A1M is primarily synthesized in the liver where it is secreted into the blood. It 
passes through the vessel wall into the extracellular matrix and/or is taken up intracellularly. After contributing to 
tissue housekeeping by radical- and heme-binding, mitochondrial protection and tissue repair, it is transported to 
the kidneys where it is filtrated in the glomeruli. Finally, it is reabsorbed in the tubuli and broken down together with 
heme and/or radicals.  
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Molecular mechanisms 
A1M is a protein with several different molecular mechanisms and protective 
functions, which have been studied both in vivo and in vitro. The mechanisms and 
functions can be divided into two different categories; immunoregulation and anti-
oxidation, where that latter is of primary focus in this work.  
Reduction 
A1M has been shown to possess enzymatic reductase/dehydrogenase properties 
with several different organic and inorganic substrates (Figure 10A). A1M could 
reduce the heme proteins metHb and cytochrome c, as well as free iron and the 
synthetic molecule nitro blue tetrazolium (NBT)[149]. In the presence of ascorbate, 
NADH or NADPH, a catalytic reductase effect was seen. The reductase and 
dehydrogenase ability of A1M was found to be dependent on Cys34 and the three 
residues Lys92, 118 and 130, which are all close to each other at the open end of the 
A1M barrel. It was speculated that the three lysyl residues create a positively 
charged microenvironment around the Cys34, which lowers the pKa of the free thiol, 
favoring its oxidation. Also, A1M could, in a Cys34 dependent reaction, reduce the 
synthetic radical ABTS (2,2’-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)) 
[116].  
Reduction of physiological substrates, both intra- and extracellular, has been shown 
for A1M. Using the erythroid cell line K562, A1M was found to decrease the 
amount of oxidized molecules in the cytosol, more specifically reduce the thiol 
groups of cytosolic proteins [144]. Additionally, the amount of carbonyl groups on 
oxidized collagen was significantly reduced by A1M with the reaction entirely 
dependent on Cys34 but only partially dependent on Lys92, 118 and 130 [142,147]. 
More recently, the role of A1M in knee injuries, where bleeding, subsequent 
inflammation and oxidative stress was studied. A correlation was found between 
increased A1M concentrations and a decrease in carbonyl groups [150]. However, 
the chemical mechanism of action during the reduction of carbonyl groups by A1M 
has not been shown in detail yet.  
Radical scavenging 
The ability of A1M to bind and neutralize radicals has been studied using the 
synthetic radical ABTS [116]. The reaction between A1M and ABTS has been 
shown to involve a Cys34-catalyzed reduction, resulting in covalent trapping of the 
radical metabolites to different amino acid side chains on A1M. During the reaction, 
A1M reduces 5-6 ABTS molecules and, in a semi catalytic mechanism, covalently 
traps 3 additional ABTS radicals by attaching them to amino acid side chains, where 
ABTS-adducts on tyrosyl side chains Tyr22 and Tyr132 were identified (Figure 
10B). Additionally, the side chains of Lys69, 92, 118 and 130 of A1M have been 
shown to be covalently modified in vivo [118,151], possibly as a result of radical 
trapping. This is supported by a report showing that urine A1M from hemodialysis 
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patient carried the lysyl modification 3-OH-kynurenine, which is a tryptophan 
metabolite known to form free radicals [152]. The lysyl side chains Lys92, 118 and 
130 may therefore play an important role in both the lowering of the pKa of Cys34 
and as electron donors during radical trapping. Cys34 has also been found to be 
modified by unidentified oxidation products in vivo, potentially contributing to the 
brown color of the protein [153].  
A1M has been described as a “radical sink” due to the fact that after reacting with a 
radical, both the radicals and A1M become electron neutral and thereby do not cause 
any further oxidative stress. A1M purified from urine is heavily modified and brown 
colored. This is not seen in other proteins isolated from urine, such as albumin, 
which suggest that the radical scavenging is not a non-specific protein modification 
but an A1M-specific reaction.  
Heme binding and degradation 
A1M binds heme and the apparent dissociation constant is approximately 10-6 
[154,155]. The ability of A1M to bind heme has been conserved through evolution 
and has been found to take place in plasma from man, rat, mouse cow, guinea pig, 
plaice and chicken [155]. When human recombinant A1M binds heme, a trimeric 
A1M/heme complex is formed, where each A1M molecule binds two heme groups, 
i.e. [(heme)2(A1M)]3 [156]. The crystal structure of A1M has revealed a potential
heme-binding site, which is similar to those seen in the CYP family, located at loop
1 (Cys34-Pro35) [115]. A possible covalent binding has also been shown, which
remained after boiling in SDS [154,155]. More recently, A1M was confirmed to have
two heme binding sites, where one of them showed a higher heme binding affinity
[157]. The two heme binding sites were suggested by molecular simulation to be
located in the lipocalin pocket, in close proximity to Lys92, 118 and 130, and more
superficially, between loop 1 and 4 with involvement of Cys34 and His123 [158]
(Figure 10C).
A processed form of A1M with heme degrading abilities, called t-A1M 
(t=truncated), was shown to be generated when full length A1M reacted with lysed 
RBCs or purified Hb [154]. The degradation of heme by t-A1M results in 
heterogenous chromophores being bound to A1M. Formation of t-A1M has been 
shown to occur in vivo and has been found in the skin, urine and placenta [154,159-
161].  
A1M also interacts with the heme-containing enzyme myeloperoxidase (MPO), 
which is a protein that catalyzes the production of free radicals and hypochlorite 
after being released by neutrophils during inflammation due to a bacterial infection 
[162]. When exposed to MPO, A1M was proteolytically cleaved, forming t-A1M, 
which contains iron and heme-degradation products. Additionally, A1M inhibited 
MPO- and H2O2-induced oxidation of LDL.  
43 
Regulation of AMBP expression 
As described above, the AMBP gene is, similar to many other enzymatic anti-
oxidants, regulated by the KEAP1/NRF2 system [128,129]. The up-regulation of 
A1M, both mRNA and protein, after exposure to oxidative stress conditions with 
H2O2, OH•, Hb and heme, has been shown to occur in human cell lines, primary skin 
keratinocytes and skin and retina explants [142,163,164]. Up-regulation of A1M 
during oxidative stress is also supported by in vivo data. Using samples from pre-
eclampsia patients, a correlation was found between the concentration of A1M in 
plasma and placenta tissue and Hb, as well as between A1M and the oxidative stress 
markers protein carbonyls groups and the plasma peroxidation capacity [161].  
Protective functions 
The molecular mechanisms described above makes A1M a potential protector 
against oxidative damage to cells and tissues. A1M can function as a radical sink, 
which removes oxidants and free radicals from the tissues, including Hb, free heme 
and iron. After binding and/or neutralizing the radicals, A1M is transported to the 
kidneys where it is degraded and/or excreted in the urine. The protective functions 
of A1M in cell, organ and animal models are presented below.  
Cell models 
Several studies have shown in vitro protective effects of A1M in cell cultures 
exposed to Hb, heme and free radicals. Exogenously added A1M prevented intra-
cellular oxidation and up-regulation of HO-1 in primary keratinocytes and the 
Figure 10. Molecular mechanisms of A1M. (A) Reductase properties. The pKa of Cys34 is lowered by Lys92, 118 
and 130. Electrons transferred from Cys34 can reduce various substrates. Electron-donating cofactors NADH, 
NADPH and ascorbate can regenerate the thiolyl radical, which makes the reduction faster and catalytic. (B) 
Radical trapping mechanism based on reaction with the synthetical radical ABTS. Similar to (A), the Cys34 
transfers an electron to a substrate, which in this case is a radical. Without the presence of electron-donating 
cofactors, the resulting thiolyl radical is regenerated by intramolecular reactions with Tyr22 and 132, producing 
tyrosyl radicals. The tyrosyl radicals then react with another radical substrate, creating a stable Tyr-radical adduct. 
(C) Heme-binding properties. Two heme-binding sites have been found. The first is located within the lipocalin 
pocket, in close proximity to Lys92, 118 and 130. The second binding site is located more superficially and involves
Cys34 and His123. 
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erythroid cell line K562, after exposure to heme or H2O2 and OH• generated by the 
Fenton reaction [142,165]. Additionally, silencing of the endogenous A1M 
expression by addition of siRNA resulted in an increased cytosol oxidation [165]. 
When exposing the K562 cells to 200 µM heme, more than 50% of the cells were 
lysed. Addition of 2 µM of A1M reduced the proportion of lysed cells to 15%. In a 
more recent study, the lysis of human (adult and fetal) and murine RBCs by 
spontaneous, osmotic, heme and radical-induced hemolysis was significantly 
reduced through addition of A1M [25]. The protection by A1M against heme-
induced hemolysis was shown to be more potent than that of hemopexin, vitamin C 
and Trolox (vitamin E). Moreover, addition of A1M to K562 cells, keratinocytes 
and liver cells exposed to heme and H2O2 inhibited mitochondrial swelling and 
reversed the severely abrogated ATP production of the mitochondria [146]. Further-
more, induction of ER-stress by heme in aortic smooth muscle cells was shown to 
be completely inhibited when adding A1M to the cell medium [166]. Induction of 
oxidative stress in cell cultures of retinal epithelial cells through illumination 
together with the photosensitizer riboflavin, could be partly inhibited by addition of 
A1M, shown by a decreased expression of HO-1 and the cell cycle regulator p21 
[167]. Finally, A1M showed a protective effect against heme induced damage to 
primary kidney cells (RPTEC) and cells from the kidney cell line HK2. Treatment 
with A1M resulted in a decreased expression of stress-related genes, preservation 
of the mitochondrial respiration and reduced activation of the Nrf2-pathway [168]. 
Alpha particle radiation of cells causes damage not only to the irradiated cells, but 
also to the adjacent bystander cells, which is thought to be caused by oxidants and 
free radicals. Addition of A1M inhibited the propagation of cell death induced by 
radiation of cultured liver cells [147,169]. The cells were irradiated with a low dose 
of alpha particles in a small restricted area. Addition of A1M to the cell cultures 
prior to radiation showed a decreased number of dead cells (50% reduction) in the 
directly hit cells and by 100% in the bystander cells. It also completely inhibited the 
irradiation induced apoptosis, formation of carbonyl groups and up-regulation of 
HO-1, p21 and p53.  
Organ models 
Using skin explants, exogenously added A1M was shown to inhibit heme-induced 
damage, up-regulation of antioxidation and cell cycle regulating genes and the 
formation of carbonyl groups [142]. A1M was found to be localized ubiquitously in 
the dermal and epidermal layers of the skin, and the expression of A1M was also 
upregulated when exposing the skin explants to heme or OH• generated by the 
Fenton reaction. To mimic damages to the placenta during preeclampsia, ex vivo 
perfusion with Hb in the fetal circulation was used. This lead to a significant 
increase in perfusion pressure, leakage of Hb from fetal to maternal circulation, 
morphological damage and up-regulation of genes connected to oxidative stress, 
immune response and apoptosis [170]. Addition of A1M to the maternal circulation, 
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mimicking a potential clinical setting, abrogated the Hb leakage, morphological 
damage and up-regulation of stress genes.  
The studies on skin explants and placenta also gave knowledge on the ability of 
A1M to protect the ECM against oxidative stress. Destruction of collagen fibrils, 
through addition of Hb, heme or Fenton reaction-generated OH•, could be 
completely inhibited by adding A1M [142]. Also, addition of A1M after the 
destruction had taken place repaired the collagen fibrils. The placentas infused with 
A1M showed a significant increase in expression of ECM genes, and the amount of 
collagen fibrils observed was increased drastically [170].  
Animal models 
In a study where rats were continuously infused with HbF, A1M was shown to 
prevent kidney damage [171]. The infusion of HbF resulted in an apparent increased 
glomerular permeability, which was almost completely reversed when treated with 
A1M. In another study, the effect of infused HbF in pregnant rabbits with or without 
co-administration of A1M, was studied [172]. The rabbits developed proteinuria and 
had an increased glomerular permeability, where both were ameliorated by co-
administration of A1M. Transmission electron microscopy analysis of the kidneys 
and placenta showed both intra- and extracellular damage. Co-administration of 
A1M resulted in significantly reduced structural and cellular changes. In a more 
recent study, the effect of A1M treatment against damage induced by extracellular 
Hb during intraventricular hemorrhage (IVH) in preterm infants was studied in a 
rabbit pup model [173]. By injection of A1M into the periventricular white matter 
regions after induction of IVH, a decrease in structural tissue and mitochondrial 
damage and a reduced expression of proinflammatory genes was seen. This suggests 
a potential role for A1M as a neuroprotective treatment against IVH in preterm 
infants.  
Preeclampsia (PE) is associated with oxidative stress where extracellular Hb has 
been identified as a plausible causative factor [174]. PE is a serious pregnancy-
related condition that causes both maternal and fetal morbidity and mortality. PE 
complicates approximately 2-8% of pregnancies and it is the leading cause of 
maternal death in low income countries [175]. The potential use of A1M as a 
treatment against PE was investigated using a pregnant ewe model, where 
starvation-induced hemolysis resulted in the release of extracellular Hb, heme and 
free radicals [176]. All starvation-induced PE-like symptoms, e.g. increased levels 
of the hemolysis marker bilirubin, structural damage to the placenta and kidneys 
and increased glomerular permeability, were all ameliorated by infusion of A1M.  
The therapeutic potential of A1M against PE was further studied using the Stork-
head box 1 (STOX1) PE mouse model, where pregnant females develop severe and 
early onset manifestations, similar to those seen in human PE, e.g. gestational 
hypertension, proteinuria and organ alterations [177]. Infusion of A1M was shown 
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to significantly reduce the gestational hypertension, the levels of hypoxia and 
nitrative stress in the placenta and reduce the cellular damage in both the kidney and 
the placenta.  
In a mouse model, A1M was evaluated as a therapeutic agent against oxidative stress 
in the kidneys as a result of treating metastatic neuroendocrine tumors with peptide 
receptor radionuclide therapy (PRRT). PRRT uses radiolabeled peptides that target 
cancer cells and eradicates them through irradiation damage. However, the peptides 
are also retained in the kidneys due to glomerular filtration, causing irradiation 
damage in this organ. In a first study, on the pharmacokinetics and biodistribution 
of A1M and radiolabeled peptides in mice, it was shown that both molecules are 
localized to the kidney cortex [178]. Immunohistochemistry and fluorescence 
microscopy revealed a co-localization in the epithelial cells in the proximal tubules. 
In a second study, the mice where treated with PRRT, which resulted in DNA 
double-strand breaks in the renal cortex, up-regulation of apoptosis and stress 
related genes, proteinuria, kidney lesions and increased animal deaths, all of which 
were suppressed by coadministration of A1M [179]. In a third study, the effect of 
coadministration of A1M during PRRT treatment on tumor killing was evaluated in 
tumor bearing mice. The results from the treatment with and without A1M showed 
no statistical significant difference between the groups, demonstrating that A1M 
does not affect tumor killing [180].  
The potential effect of A1M treatment against kidney damage during glycerol-
induced rhabdomyolysis was evaluated using a mouse model [181]. Glycerol 
injections into the thigh muscle ruptures the muscle, releasing myoglobin, heme, 
radicals and other tissue components. A mild dose (2 ml/kg) did not affect 
creatinine/blood urea nitrogen (BUN) levels but a massive increase in the stress 
related genes HO-1 and HSP70 was seen. Injections of A1M inhibited or reversed 
the up-regulation of both stress genes.  
Table 1. Summary of animal studies performed to evaluate the therapeutic potential of A1M.  
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Clinical use of A1M 
Therapeutic potential 
Oxidative stress is associated with several different diseases and conditions where 
oxidation of cells and tissues causes a buildup of reactive free radicals. The state of 
oxidative stress can lead to tissue damage and subsequent development of disease. 
The use of drugs with antioxidative properties against diseases caused by oxidative 
stress or for prophylactic purposes has been tried in the past decades but with no 
successful outcome [182].  
The ability of A1M to reduce oxidized molecules, bind free heme groups and to 
scavenge free radicals, makes it a good candidate for treatment in conditions where 
oxidants, radicals, Hb and/or heme play an important role in the pathology of the 
disease. In vivo data has shown, as described above, that A1M is an effective 
treatment against experimental PE in mice, rats and sheep. It has also been shown 
that A1M can reduce side effects from PRRT treatment of neuroendocrine tumors 
in mice, by reducing the damage to the kidneys. Additionally, it was shown to 
reduce rhabdomyolysis induced kidney damage in mice. Finally, a study on rabbit 
pups has shown promising results for A1M as a treatment against extracellular Hb 
toxicity in IVH in preterm infants.  
A1M has several advantages over some other much studied antioxidants and radical 
scavengers, such as vitamin E and C. Firstly, the molar capacity of A1M in 
binding/buffering of radicals is higher than vitamin C and E (1:10 vs. 1:1). Secondly, 
A1M occurs naturally in the body and possesses a metabolic route which ensures a 
controlled delivery and clearance. Thirdly, when the radicals are bound to A1M, it 
remains electroneutral and does not cause any further oxidative stress to the 
surrounding tissues. 
Even though the therapeutic opportunities for A1M are plentiful, more research is 
needed before it can be clinically used. 
A1M as a biomarker in PE 
Recently, several reports have focused on predicting PE early during pregnancy or 
to avoid or reduce later complications. Algorithms have primarily been based on 
placental biomarkers such as soluble FMS-like tyrosine kinase 1 (s-FLT-1), 
placental growth factor (PLGF) and pregnancy-associated plasma protein A (PAPP-
A) [183]. More recently, an alternative model was suggested, which is based on the 
levels of HbF and A1M [184]. The model had a prediction rate of 69% at a false 
positive rate of 5%. A notable advantage of this model was that it performed equally 
well without uterine artery Doppler pulsatility index, making it more suitable for 
low income countries. Subsequent studies have verified the increase of plasma A1M 
and HbF during early pregnancy, in women later developing PE [185,186]. 
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Additionally, a study investigating the plasma levels of extracellular HbF and the 
heme scavenging proteins A1M, Hpx and Hp in women with PE at term, showed 
similar results [187]. Women with PE had increased plasma levels of A1M and HbF, 
and a decreased level of Hpx and Hp, suggesting a potential role of HbF and the 
heme scavenging proteins as biomarkers of PE. The plasma levels of A1M have also 
been found to be higher in the late second trimester in women with severe PE 
compared to non-severe [188], suggesting a possible use for A1M as a biomarker of 
severe PE.  
Recombinant A1M 
rA1M 
The A1M used in these studies is a recombinant protein expressed as inclusion 
bodies in E.coli [189]. Briefly, E.coli cells were transformed with a plasmid 
containing the human A1M gene, with the addition of a polyhistidine-tag in the N-
terminal. The protein expression was induced using IPTG and after harvesting the 
cells, the inclusion bodies, i.e. protein precipitates, were carefully washed 
repeatedly, dissolved in 6M guanidine-HCl and applied on a Ni-NTA column. The 
bound proteins were eluted with imidazole, and the A1M containing fractions were 
mixed with water and reduced glutathione and then dripped into a refolding buffer 
containing oxidized glutathione. The samples were then dialyzed twice and further 
purified by size-exclusion chromatography. UV circular dichroism and radio 
immunoassay were used to determine that the A1M was correctly folded. 
Recombinant A1M (rA1M) has been shown to be fully functional in comparison 
with endogenous A1M [116,149]. 
C34S 
Several different rA1M variants have been produced where amino acids shown to 
be important for the molecular mechanisms of A1M have been substituted. One of 
them, which has been used in this work is C34S, where the cysteine in position 34 
has been replaced by a serine. Studies using C34S have revealed an important role 
of Cys34 in the protection against irradiation damage and in cellular uptake [147] 
and in reduction of radicals [116] and carbonyl groups on oxidized collagen [142]. 
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A1M-035  
Studies using rA1M has shown that A1M 
can protect against Hb, heme and ROS 
induced damage to cells and tissues both in 
vitro and in vivo. However, rA1M, which 
lacks glycosylation, has a reduced solubility 
and stability when compared to A1M 
purified from plasma or urine. Due to its 
rather poor solubility and stability it is 
difficult to obtain highly concentrated 
solutions and to store it for longer times in 
physiological buffers. This limits its use as a 
drug for human use. To address this 
problem, rA1M variants with different 
amino acid substitutions were screened for 
physiochemical and enzymatic properties, 
which resulted in an rA1M variant called 
A1M-035 [181]. An important difference 
between rA1M and endogenous A1M is the 
presence of two N-glycans attached to amino acids N17 and N96 in endogenous 
A1M. The rationale behind the design of A1M-035 was to add a negative charge to 
N17 and N96 by replacing them with the negatively charged amino acid aspartic 
acid (D). Additionally, R66 was substituted with a histidine, which is present in all 
rodent A1M homologues. A1M-035 was shown to have improved stability and 
solubility while having an intact heme-binding, reductase, antioxidation and cell 
protecting ability. This makes A1M-035 a more suitable candidate for future drug 
development.  
  
Figure 11. 3D-structure of 035-A1M. Amino 
acid substitutions R66H, N96D and N17D are 
shown with their sidechains in blue. Cys34 is 
displayed with its sidechain in red.  
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Aim 
The overall aim of this thesis was to further investigate the possible biological roles 
of A1M. The more specific aims were to:  
1. Characterize the A1M knockout mice (A1M-KO) and thereby gain 
additional knowledge about in vivo functions of A1M and the co-expression 
of A1M and bikunin.  
2. Study the potential biological role of A1M as a protector of red blood cells 
in vitro and in vivo.  
3. Investigate the interaction between A1M and heparin/heparan sulfate in 
vitro and in vivo and its potential use during purification of A1M from 
human plasma. 
4. Analyze the interaction between riboflavin and A1M during illumination 
and the protective effect of A1M against riboflavin induced damage to 
retinal epithelial cells.  
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Results and discussion 
A1M is needed during bikunin synthesis 
Reasons behind A1M and bikunin co-expression from the AMBP gene has never 
been established and no common functions of the two proteins have been found after 
their secretion from the liver. Two proteins sharing the same gene, yet having no 
common function, is to our knowledge a very rare phenomenon. However, the 
AMBP gene is conserved in all species found to express A1M, indicating that there 
must be a biological explanation to why the two proteins are expressed together. 
Recently, we developed an A1M knockout mouse (A1M-KO) with a selective 
deletion of the A1M exons (exons 2-6), resulting in complete loss of A1M while 
maintaining the expression of bikunin. This new mouse model gave us a novel tool 
to use when studying the biological reason behind the co-expression of the two 
proteins. In the A1M-KO mice, the deletion of the A1M exons was achieved using 
Cre-Lox recombination, where two loxP sites were inserted into the introns after 
exon 1 and 6. The localization of the loxP sites and the difference between the WT 
and KO alleles are shown in Figure 12. 
 
The A1M-KO mice had no detectable levels of A1M in plasma (Figure 13A, upper 
panel) and no A1M mRNA (Figure 13B) was detected in the liver. The mRNA 
levels of bikunin in the liver were found to be slightly increased compared to the 
wildtype mice (Figure 13C), whereas decreased levels of the bikunin complexes IαI 
Figure 12. Graphical overview of the removal of the A1M exons in the A1M-KO mice. Exons 1-6 (white boxes) 
represent A1M and exons 7-10 (black boxes) represents bikunin. The exons were removed through cre deletion 
and P1, P2 and P3 represent the primers used for genotyping of the mice. Figure from [127]. 
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and PαI were seen in plasma compared to the wildtype mice (Figure 13A, lower 
panel). A possible explanation for the discrepancy between the mRNA and protein 
levels include the chaperone function of A1M during the folding and subsequent 
attachment of the heavy chains to bikunin, and therefore, less bikunin is folded 
correctly and secreted in mice lacking A1M. Western blot analysis of liver 
homogenates showed the presence of two new bands exclusively found in the KO 
mice (Figure 13D). These new bands presumably represent free uncomplexed 
bikunin-forms, further supporting the requirement of A1M being present during the 
posttranslational handling of bikunin. In addition, one of the bands carried the signal 
peptide of the AMBP precursor, suggesting incomplete cleavage of the signal 
peptide. Furthermore, the KO mice showed signs of hepatic ER-stress, measured by 
the mRNA levels of the UPR mediators XBP1s and CHOP (Figure 13E and F), 
possibly partly due to the misfolded bikunin accumulating over time, resulting in 
activation of the UPR.  
A possible chaperone mechanism could be to keep the free thiol groups of bikunin 
reduced to ensure that proper disulfide bond formation occurs. Bikunin contains six 
disulfide bonds, making it sensitive to incorrect disulfide bond formations, which 
would result in misfolding of the protein. Another potential function of A1M could 
Figure 13. (A) SDS-PAGE followed by Western blot analysis of plasma using antibodies directed at A1M (upper 
panel) and bikunin (lower panel) from KO and WT mice at age 1.5, 6 and 12 months. (B,C,E,F) RT-PCR analysis 
of A1M, bikunin, XBP1s and CHOP gene expression in liver from KO and WT mice aged 1.5, 6 and 12 months. 
The results are shown as boxplots with medians, 25th and 75th percentiles (box) and min to max (whiskers). Animals 
per group: 1.5 m: WT n = 5 KO n = 10, 6 m: WT n = 10 KO n = 9, 12 m: WT n = 15 KO n = 14. Statistical testing of 
differences between groups was performed with Mann-Whitney U tests. **p < 0.01, ****p < 0.0001. (D) SDS-PAGE 
(without β-mercaptoethanol), followed by western blot analysis using antibodies directed at bikunin on liver 
homogenates from 4-month-old mice. Figure adapted from [127]. 
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be to facilitate the addition of the CS and the heavy chains to bikunin. In paper III, 
we revealed a novel function of A1M as a heparin and HS binding protein. 
Considering the similarity of CS and heparin/HS, A1M could potentially bind to CS 
to facilitate the attachment to bikunin as well as assisting during the subsequent 
complex formation with the heavy chains.  
These data suggest that A1M is a requirement for optimal production of bikunin in 
the liver, which partly explains the reason for the co-synthesis of A1M and bikunin. 
Studies on bikunin knockout mice, which lack the expression of bikunin but retain 
preserved A1M expression, found no evidence of reduced levels of A1M in the 
plasma [190], suggesting that bikunin is not a requirement for the production of 
A1M.  
56 
Protection against oxidative stress in different cell types 
Red blood cells 
The ability of A1M to protect against oxidative stress induced damage has been 
studied in a wide range of different cell types. In paper II, we hypothesized that 
A1M could protect RBCs against spontaneous, heme-, radical- (Fenton reaction), or 
osmotic-induced hemolysis. The extent of hemolysis was assessed by measuring the 
amount of lactate dehydrogenase (LDH) and hemoglobin in the medium after 
exposure to different stressors. The results showed a statistically significant 
protective effect of A1M against spontaneous hemolysis after 1 and 3 h (Figure 14A 
and B). The protective effect of A1M was also found to be significantly increased 
compared to the lipocalin orosomucoid, indicating a specificity of A1M. Moreover, 
A1M was also shown to protect against heme- and Fenton-induced hemolysis after 
3 and 22 h (Figure 14C-F). Finally, the degree of hemolysis after exposure to 
osmotic stress was significantly reduced when adding A1M (Figure 14G and H). 
Figure 14. Protection of RBCs by A1M against spontaneous-, heme- and osmotic-induced hemolysis. 
(A,B) Hemolysis, determined as LDH release from the cells, after incubation of washed RBCs (n = 3) with 
orosomucoid (110 or 220 µg/ml), A1M-wt (110 or 220 µg/ml) or A1M-035 (110 or 220 µg/ml) for 1 h (A) 
or 3 h (B). (C,D) Hemolysis, determined as LDH release from the cells, after addition of heme (30 µM) to 
washed RBCs with A1M-wt (220 µg/ml) or A1M-035 (220 µg/ml) after 3 h (C) and 22 h (D) of incubation. 
(E,F) Hemolysis, determined as Hb release from the cells, after addition of Fenton reactants to washed 
RBCs with A1M-wt (220 µg/ml) or A1M-035 (220 µg/ml) after 3 h (E) and 22 h (F) of incubation. (G,H) 
Hemolysis, determined as LDH release from the cells, after addition of 42% H2O (A) or 45% H2O to 
washed RBCs with or without A1M-wt (220 µg/ml). Values are shown as mean ± SD and the differencse 
between groups were calculated using one-way ANOVA with post hoc Sidak (A-D) or unpaired two-tailed 
t-test (E-H). ***p < 0.001, ****p < 0.0001. Figure adapted from [25]. 
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To further study the protective role of A1M against hemolysis, comparisons were 
made with the heme binding protein hemopexin (Hpx) and the antioxidant 
compounds Trolox (vitamin E) and ascorbic acid (vitamin C). The results showed a 
superior protective effect of A1M compared to hemopexin against spontaneously 
induced (Figure 15A), heme-induced (Figure 15B) and osmosis-induced hemolysis 
(Figure 15C). Addition of Trolox or ascorbic acid showed no protection against 
spontaneously induced hemolysis, whereas A1M significantly reduced the amount 
of hemolysis (Figure 15D).  
 
 
During hemolysis, Hb leaks from its protective intracellular environment into the 
circulation. Here, it undergoes autooxidation, generating radicals that cause damage 
to the membranes of nearby RBCs. Additionally, Hb is broken down, releasing its 
heme groups, causing further damage to the membranes of the nearby RBCs. The 
Figure 15. Comparison of protection against hemolysis between A1M, Hpx, Trolox and ascorbic acid. (A-C) 
Hemolysis, determined as LDH release from the cells, after addition increasing concentrations of A1M-wt or Hpx 
to washed RBCs exposed to spontaneous stress for 5 h (A), heme-induced stress (30 µM heme) for 3 h (B) or 
osmotic stress (42% H2O) for 2 h (C). (D) Hemolysis, determined as Hb release from the cells, after incubation of 
washed RBCs with ascorbic acid (220 µg/ml), Trolox (220 µg/ml) or A1M (220 µg/ml) for 5 h. Values are shown as 
mean ± SD and the differencse between groups were calculated using one-way ANOVA with post hoc Sidak. ***p 
< 0.001, ****p < 0.0001. Figure from [25]. 
58 
generation of extracellular Hb and free heme groups creates a feed-forward loop 
resulting in even more hemolysis. The mechanism behind the protective effect of 
A1M could be due to the neutralization of the free heme groups and radicals 
produced by the extracellular Hb and thereby stopping the feed-forward loop. The 
superior protective effect of A1M when compared to hemopexin indicates the 
involvement of more than the neutralization of free heme groups. However, the 
reducing effect alone, which was examined using Trolox and ascorbic acid, did not 
provide any protection. It may be speculated that A1M with is combination of heme-
binding, reduction and radical binding, has evolved a unique RBC protective 
function.  
Retinal epithelial cells 
In paper IV we examined the protective role of A1M against light-induced damage 
to retinal epithelial cells. The light-induced damage was generated by adding the 
photosensitizer riboflavin to the cell media followed by illumination. This produces 
riboflavin radicals, which can both directly oxidize cell components and generate 
more harmful ROS, which thereby exposes the cells to oxidative stress. Addition of 
A1M to the cell media prior to illumination resulted in a statistically significantly 
reduced expression of the cell cycle regulator p21 (Figure 16A). Reduced expression 
of the oxidative stress marker HO-1 (HMOX1in the Figure) failed to reach 
significance, but a trend was seen where increasing concentrations of A1M reduced 
the expression (Figure 16B).  
Figure 16. RT-PCR analysis of ARPE19 cells. (A,B) Relative mRNA levels of p21 and HMOX1 in ARPE19 
cells after addition of riboflavin and A1M follwed by illumination. Values are shown as fold change (2-ΔΔCt). 
Statistical comparisons of differences between samples were performed using one-way ANOVA with post 
hoc Sidak. *p < 0.05, **p < 0.01. Figure from [167]. 
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These results suggest a protective effect of A1M against riboflavin radicals, which 
can be seen as a decrease in expression of stress response genes. The ability of A1M 
to protect against riboflavin induced damage could potentially take place in light-
exposed parts of the body, such as in the skin and eyes. Both A1M and riboflavin is 
present in the skin and eyes, making the interaction plausible.  
These results, from paper II and IV, give further knowledge into the cell protecting 
abilities of A1M. Two new cell types, RBCs and retinal epithelial cells, have been 
added to the long list of the cell types that A1M can protect against oxidative stress. 
Paradoxically, this might make it even more challenging to establish the main 
biological target cell of A1M. Contrarily, the rather promiscuous ways of A1M, 
regarding both its binding targets and its cell type interactions, might be due to the 
fact that there is no main biological target cell and that the protection is of a more 
general nature. However, more research on the topic is needed to reach a final 
conclusion.  
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A1M binds to heparin and heparan sulfate and can be 
purified from plasma using heparin Sepharose 
Recently, heparin binding proteins were detected in urine using affinity 
chromatography and mass spectrometry [105], which included the detection of 
AMBP. However, since AMBP is not found in urine, it could not be determined 
whether it was A1M or bikunin that was detected. The authors found three heparin 
binding sites within the AMBP sequence, suggested to play an important role in the 
binding of AMBP to heparin. In paper III we further investigated the molecular 
interactions between A1M and heparin/heparan sulfate.  
We showed that it is possible to purify A1M from human plasma using heparin 
affinity chromatography and size exclusion chromatography. A flowchart with the 
required steps is shown in Figure 19. The starting material, 400 ml human plasma 
diluted with 0.2M NaCl-buffer, is applied to a column with heparin Sepharose, 
which separates A1M from plasma proteins with no or weak affinity to heparin 
(Figure 19A and D). Since several other heparin binding proteins are eluted with 
A1M (Figure 19D), the sample is further purified using size exclusion 
chromatography (Figure 19B). A more purified A1M fraction is obtained, shown by 
SDS-PAGE and Western blotting analysis (Figure 19D). To achieve a completely 
pure A1M fraction, an additional size exclusion step is performed (Figure 19C).  
Figure 19. Purification of A1M from plasma using heparin-Sepharose and size exclusion chromatography. (A) 
Flowchart with the steps required for purification of A1M from plasma. (B) UV-absorbance (280 nm) of fractions eluted 
from the first size exclusion chromatography (SEC 1). (C) UV-absorbance (280 nm) of fractions eluted from the second 
size exclusion chromatography step (SEC 2). (D) Coomassie total protein stain (left panel) of heparin sepharose, SEC 
1 and SEC 2. Western blot of heparin sepharose, SEC 1 and SEC 2 with rabbit anti A1M antibodies (right panel).  
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The nature of the interaction was further studied and found to be predominantly 
driven by electrostatic interactions. The binding strength was shown to be dependent 
on the degree of sulfation of the heparan sulfate and was suppressed by high ionic 
strength. The binding was further examined using hydrogen deuterium exchange 
mass spectrometry (HDX-MS). The HDX-MS showed two regions, amino acids 29-
44 and 162-180, with reduced deuterium uptake, indicating potential binding areas. 
These were found to be located on the outside of the barrel shaped A1M molecule 
(Figure 20). In the paper described above, where the authors detected AMBP as a 
heparin binding protein in urine, three different heparin binding motifs were found 
in the AMBP molecule. Interestingly, none of these coincide with the binding 
regions found with HDX-MS.  
 
Purification of A1M from plasma in large quantities is technically difficult. Affinity 
chromatography using specific antibodies is costly, the heterogenous charge of 
A1M makes ion exchange chromatography and electrophoretic methods less 
efficient, and the low concentration in plasma results in low yields. The heparin 
binding function, which is described in paper III, could represent a useful and cost-
effective tool for purifying A1M from plasma. The method has several advantages 
compared to the methods currently used. For example, the elution of A1M from 
heparin is performed with NaCl, which is mild and keeps the protein functional. 
Purification from plasma might also be a more attractive alternative to recombinant 
A1M produced in E.coli for clinical drug use, since the plasma A1M is glycosylated 
and therefore more stable. Additionally, plasma A1M does not contain a His-tag, 
making it less likely to cause antigenic reactions in the body.   
Figure 20. Front and sideview of a 3D model of A1M with potential heparin binding areas highlighted in green. The 
potential heparin binding areas, amino acids 29-44 and 162-180, are based on reduced deuterium uptake during 
hydrogen deuterium exchange mass spectrometry (HDX-MS). 
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A1M binds to cell surfaces and is internalized 
In paper III we studied the binding 
interaction between A1M and 
heparin/heparan sulfate (HS). A1M was 
found to bind to both heparin and HS and 
the binding was shown to be of 
electrostatic nature. HS is present on the 
surface of most cells in the body, making 
it a plausible binding target for A1M. 
Immunohistochemistry with antibodies 
directed at A1M and HS on endothelial 
cells revealed a co-localization (Figure 
17A). The mean Pearson’s correlation 
coefficient was calculated to 0.87, 
suggesting a strong correlation. When 
treating the endothelial cells with 
heparinase, which cleaves off the surface 
bound HS, prior to adding the antibodies, 
most of the A1M signal was lost (Figure 
17B). Additionally, when using immuno-
histochemistry to analyze the co-
localization of A1M and HS in vivo in 
mice, co-localization was shown in parts 
of the kidney, skin, lung and aorta. The 
binding seen in vivo further supports a 
physiological function of the interaction.  
In paper II, we used anti-A1M antibodies, 
with gold-labeled secondary antibodies, 
to detect A1M in RBCs. Using sections from a full-term placenta with RBCs, A1M 
was detected on both the cell surface and in the cytosol (Figure 18A), which 
suggests the presence of A1M in RBCs in vivo. Additionally, washed RBCs were 
incubated with A1M for 0, 3 and 7 days, fixated, sectioned and stained with anti-
A1M and gold-labeled secondary antibodies. The results showed the presence of 
A1M both intracellularly and on the surface at all timepoints (Figure 18B).  
Figure 17. Fluorescence staining of endothelial cells 
(EA.hy926). (A) Heparan sulfate staining (green, 
upper panel), A1M staining (red, middle panel) and 
merged picture with DAPI nucleus staining (bottom 
panel). (B) Heparinase treatment (heparinase I and 
III) followed by staining with anti heparan sulfate 
(green, upper panel) and anti A1M (red, lower panel). 
(C) Pearson’s correlation coefficient of the view in the 
merged picture. 
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In both paper II and III we have shown the presence of A1M both intracellularly 
and on the cell surface of RBCs and endothelial cells. HS has been shown to be 
present on the surface of RBCs [191] and endothelial cells [192]. The presence of 
HS on the surface on both cell types could represent a potential binding site for 
A1M, from where it is further internalized through an unknown mechanism. 
Cellular uptake of A1M has previously been shown in liver cells [169], keratinocytes 
[142] and blood cells [144] and the uptake was found to be increased during apoptosis 
and irradiation. However, the uptake mechanism has not been determined. Another 
possible consequence of the binding to HS on the surface could be that the surface 
bound A1M has the potential to protect the cells against oxidants close to the plasma 
membrane, thereby preventing oxidative stress and potential hemolysis. The plasma 
membrane is sensitive to oxidation, and hydrophobic molecules such as heme can 
intercalate into the cell membrane making it more susceptible to lipid peroxidation. 
Reduction of oxidants and/or binding of heme molecules by A1M at the cell surface 
could possibly represent a biological function of A1M in vivo.   
Figure 18. In vivo detection and in vitro uptake of A1M in red blood cells (RBCs). (A) Section of a full 
term placenta with RBCs, stained with anti A1M and gold labeled secondary antibodies. Scalebar = 
500 nm. (B) Washed RBCs incubated with A1M-035 for 0, 3 or 7 days followed by fixation, 
embedding, sectioning and staining with anti A1M and gold labeled secondary antibodies. Scalebar 
= 200 nm. Figure adapted from [25]. 
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New insights on molecular mechanisms and 
physiological functions of A1M 
Radical-induced cleavage of A1M 
As described above, riboflavin, or vitamin B2, can generate ROS when illuminated 
and thereby cause oxidative stress. In paper IV we studied the interaction between 
A1M and illuminated riboflavin. The results revealed a binding of riboflavin to 
A1M and a cleavage of the A1M molecule in the N-terminal region (Figure 21A). 
The cleavage was also seen when A1M reacted with flavin adenine dinucleotide 
(FAD), which has a riboflavin molecule as its functional group (Figure 21B). No 
cleavage was seen when the incubation took place in darkness, which indicates that 
the cleavage reaction mainly occurs during illumination. Cleavage of A1M has been 
shown previously when it reacts with the synthetic radical ABTS [116]. When 
reacting with ABTS, an N-terminal peptide is cleaved off, indicating a similar 
reaction as with riboflavin. This could potentially represent a general radical 
interacting mechanism where A1M is cleaved when interacting with the radicals. 
The mechanistic and biological function of the cleavage reaction is, however, not 
known and needs to be studied further.  
Figure 21. SDS-PAGE stained with Coomassie after incubation with (A) riboflavin and (B) flavin adenine 
dinucleotide (FAD). The samples were illuminated with a fluorescent lamp (1200 lumen) at a distance of 0.2 m or 
kept in darkness for 1 h. The upper arrows indicate the full length modified A1M and the lower arrows indicate the 
cleavage product. Figure from [167]. 
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A1M regulates ER-stress and fat metabolism in vivo 
When studying the A1M-KO mice, in paper I, some unexpected physiological 
changes were seen in the mice. The lack of A1M resulted in a statistically significant 
increase in body weight in both male and female mice (Figure 22A). Additionally, 
the mice showed a tendency towards increased fat accumulation in the liver (Figure 
22B and C). A trend was also seen in the weight of the liver, spleen and heart, where 
the organs of the KO mice weighed slightly more. The underlying mechanism 
behind controlling the body weight of an organism is very complex and to a large 
extent unknown. A potential partial explanation to the increased body weight could 
be a general increase in organ weight, since the KO mice displayed a trend towards 
increased weight of the liver, spleen and heart (Figure 22D-F). The increased liver 
weight could be explained by an increased production of lipids due to the presence 
of ER-stress. ER-stress has been found to be a key contributor to the development 
of the metabolic syndrome, which includes increased body weight [193,194]. It could 
be speculated that the lack of A1M leads to ER-stress which subsequently 
contributes to the development of the metabolic syndrome.  
 
Figure 22. Analysis of body weight, liver fat and organ weights of A1M-KO and WT mice. (A) Body weight of 12-
month-old KO and WT mice. Statistical comparisons between groups were performed with Mann-Whitney U tests. 
*p < 0.05, ***p < 0.001. (B) Triglyceride content in the livers of male and female mice at the age of 12 months. (C) 
Representative sections of livers from male KO and WT mice at the age of 12 months, stained with Oil Red O. 
Scale bars = 20 µm). (D,E,F) Weight of liver, spleen and heart as percentage of body weight from 12-month-old 
male KO and WT mice. Figure from [127]. 
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A1M regulates blood cell homeostasis 
Blood analysis of whole blood from A1M-KO and WT mice showed tendencies 
towards a lower RBC count in the KO mice, and the mean corpuscular volume 
(MCV), mean corpuscular Hb (MCH) and red cell distribution width (RDW) were 
all statistically significantly increased in the KO mice (Figure 23). No differences 
were found in Hb, reticulocyte percentage and hematocrit. These changes in blood 
values indicate a steady state macrocytic anemia phenotype. The difference in size 
and width distribution could be due to a disturbance in the erythrocyte development 
or due to an increased number of immature RBCs as a response to counteract the 
lower RBC count. The lack of A1M in the KO mice could potentially lower the 
protection against hemolysis, which would explain the lower RBC count. This 
further strengthens the potential physiological role of A1M as a protector of RBCs 
in vivo.  
Figure 23. Morphology of RBCs in A1M-KO mice. Samples of whole blood from 12-month-old KO (n = 4) and WT 
(n = 5) mice were analyzed using a blood analyzer (Abacus Vet5 Diatron). The plots show RBC count, mean 
corpuscular volume (MCV), mean corpuscular Hb (MCH) and red cell distribution width (RDWs). Figure adapted 
from [25].  
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Conclusions 
The central aim of this thesis was to gain new knowledge about the different 
potential biological roles of A1M. The four studies included in the thesis have 
provided new perspectives on the topic.  
In paper I, a previously unknown role of A1M as a chaperone during bikunin 
synthesis was discovered. The chaperone function of A1M might also partially 
explain the co-expression of A1M and bikunin. The results in paper I also touched 
on a new field in the A1M research, namely obesity and the metabolic syndrome. 
More research is needed, but hopefully, follow up studies on the A1M-KO mice 
could perhaps lead to a novel method in the battle against human obesity.  
Paper II revealed a new role of A1M as a protector of RBCs against various forms 
of stress. Additionally, the presence of A1M intracellularly and on the RBC 
membrane was shown in vivo. When comparing the protective effect of A1M 
against other antioxidants or the heme binding protein hemopexin, A1M displayed 
superior protection, indicating a unique protective function of A1M. The results 
suggest that protection of RBCs in the blood stream is a plausible biological role of 
A1M.  
In paper III, the newly discovered ability of A1M to bind to heparin was studied in 
more detail. The heparin binding ability possibly represents a biological anchoring 
mechanism used by A1M to extravasate from the blood and/or bind to the surface 
of cells to protect them against oxidants or for internalization of A1M. Additionally, 
the heparin binding ability represents a useful tool for plasma purification of A1M  
Paper IV showed a new role of A1M as a protector against radicals induced through 
the illumination of riboflavin. The presence of both riboflavin and A1M in light 
exposed parts of the body suggests that the interaction is biologically relevant.  
Altogether, these studies provide additional information surrounding the multi-
faceted functions of A1M simultaneously placing them in a biologically relevant 
context. Further research will hopefully lead to a more definitive answer to the 
question regarding the biological role of A1M and finally result in the development 
of A1M as a pharmaceutical.  
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